Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Revolution Medicines (RVMD) Stock Price & Analysis
137 Followers
RVMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.08 - $31.37
Previous Close$27.86
Volume615.55K
Average Volume (3M)973.09K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$655.01M
Total Debt (Recent Filing)$65.20M
Price to Earnings (P/E)-8.8
Beta0.69
Next EarningsFeb 28, 2023
EPS Estimate-$0.82
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$31.00
EPS (TTM)-3.18
Shares Outstanding88,790,799
R-Squared0.25
Standard Deviation0.18
10 Day Avg. Volume1,240,246
30 Day Avg. Volume973,093
Price to Book (P/B)4.03
Price to Sales (P/S)121.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-14.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside11.27% Upside
Rating ConsensusStrong Buy
Alpha-0.00715
Number of Analyst Covering3
Revolution Medicines News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $14.08 and its highest was $31.37 in the past 12 months.
What is Revolution Medicines’s market cap?
Currently, no data Available
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Feb 28, 2023 which is in 32 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 07, 2022. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.842 by -$0.028.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -$0.82.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 88,790,800 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.842. Following the earnings report the stock price went down -0.607%.
Which hedge fund is a major shareholder of Revolution Medicines?
Among the largest hedge funds holding Revolution Medicines’s share is Deerfield Management Company, LP. It holds Revolution Medicines’s shares valued at 57M.
---
Revolution Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00
$31.00
Blogger Sentiment
Bullish
RVMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $87.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.62%
12-Months-Change
Fundamentals
Return on Equity
-37.11%
Trailing 12-Months
Asset Growth
12.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
---